Phase II study of VI (vincristine, irinotecan) / VPC (vincristine, pirarubicin, cyclophosphamide) / IE (ifosfamide, etoposide) / VAC (vincristine, actinomycin D, cyclophosphamide) for patients with newly diagnosed high-risk rhabdomyosarcoma. - Phase II study of VI / VPC / IE / VAC for patients with newly diagnosed high-risk rhabdomyosarcoma.

Japan Children's Cancer Group (JCCG)0 sites60 target enrollmentFebruary 1, 2017

Overview

No summary available.

Registry

who.int

Start Date

February 1, 2017

End Date

January 31, 2026

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Japan Children's Cancer Group (JCCG)

•1\) primary central nervous system rhabdomyosarcoma, positive findings of cerebrospinal fluid cytology, metastatic central nervous system rhabdomyosarcoma 2\) patients with synchronous or metachronous concomitant malignancies 3\) patients with Charcot\-Marie\-Tooth disease or varicella 4\) patients with uncontrollable complications Interstitial pneumonia, pulmonary fibrosis, severe emphysema Uncontrollable diabetes mellitus Uncontrollable hypertension Severe electrocardiogram abnormality or clinically significant heart disease(heart failure, myocardial infarction, angina pectoris) Liver failure, cirrhosis Renal failure 5\) patients with contraindication of drugs used in this study 6\) Female patients who are pregnant or breastfeeding mother or patients considering pregnancy 7\) Patients with any other inappropriate condition judged by physician